Celcuity (CELC) traded higher Thursday as investors leaned into the company’s next major clinical catalyst: top-line results from the PIK3CA-mutant cohort of its Phase 3 VIKTORIA-1 study of gedatolisib, which management has been guiding to the second quarter of 2026. Recent company commentary has kept the timeline in focus, and the market action looks consistent with pre-catalyst positioning rather than a single headline tied to a new announcement dated April 9.

Celcuity’s valuation has become increasingly tied to execution on VIKTORIA-1, following previously disclosed positive top-line outcomes in the PIK3CA wild-type cohort. With the mutant cohort now the key near-term swing factor, incremental sentiment can shift quickly on timing, investor-conference commentary, and expectations for efficacy and tolerability relative to standard-of-care backbones in HR+/HER2- advanced breast cancer.

In the last few weeks, Celcuity’s communications around its full-year 2025 results and corporate updates maintained attention on the upcoming readout window. With no obvious new SEC filing or same-day press release driving the tape, the stock’s modest gain fits a pattern often seen in clinical-stage biotech names when investors front-run a binary data catalyst and adjust exposure into liquidity pockets.